Market Movers: BGI’s Upcoming $250 Million China IPO

China’s Largest Insurer Announces $1 Billion Fin-Tech/Healthcare VC Fund
July 10, 2017
Shanghai-Israel Fund Lead $9M Round In Rapid Medical
July 23, 2017

Market Movers: BGI’s Upcoming $250 Million China IPO

 

BGI Genomics is planning for its IPO in China. As the contract sequencing and diagnostics divisions of China’s genomic company BGI, BGI Genomics expects to raise $250 million from this IPO in July, following the expected final approvals from Chinese authorities. Known as a world leader in basic science sequencing, BGI Genomics now generates 55% of its income from clinical genomic tests, especially its NIFTY prenatal test for hereditary illnesses such as Down’s syndrome.


China Med Device, LLC, provides turn-key solutions for medical device medtech companies entry into China, brings you up-to-date information on China’s medical device industry. We offer market assessment, regulatory, commercialization, funding and growth acceleration services to international medtech companies. If you have any feedback, please email us at info@ChinaMedDevice.com or visit us at www.ChinaMedDevice.com.